Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase
about
The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers.The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCNALK: a tyrosine kinase target for cancer therapy.Discovery of a potent dual ALK and EGFR T790M inhibitor.ALK alterations and inhibition in lung cancer.Targeting ALK: Precision Medicine Takes on Drug Resistance.Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.Potent Pyrimidine and Pyrrolopyrimidine Inhibitors of Testis-Specific Serine/Threonine Kinase 2 (TSSK2).Combating Drug-Resistant Mutants of Anaplastic Lymphoma Kinase with Potent and Selective Type-I1/2 Inhibitors by Stabilizing Unique DFG-Shifted Loop Conformation.Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib.The role of brigatinib in crizotinib-resistant non-small cell lung cancer.Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.Best Practices in Treatment Selection for Patients With Advanced NSCLC.Treating ALK-positive non-small cell lung cancer.ALK inhibitors, resistance development, clinical trials.Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments.Novel organophosphorus aminopyrimidines as unique structural DNA-targeting membrane active inhibitors towards drug-resistant methicillin-resistantHypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literatureAutochthonous murine models for the study of smoker and never-smoker associated lung cancersPharmacologic characterization of CT-711, a novel dual inhibitor of ALK and c-MetCanadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer
P2860
Q33553447-85D2BE9A-E912-424B-95DF-5718DB0D8D75Q37305906-5BF7EAA6-F4AB-450A-9BFD-499F7B607385Q37518624-B0B25555-1AEC-4507-BC94-EBD4EB2594DFQ38702793-144E9672-B632-4B2C-9E1F-F2C2BD5A1EADQ38820412-F6D83640-02D6-4018-A216-82244474A7B8Q39103431-9D4888C2-1FCF-4D0E-BC6D-F4FD59B61355Q39278116-881A7B16-159D-4782-AF7A-87F5BEFF9B87Q42315652-CE41ACDB-A464-426F-9DA2-0FAF8FC60914Q45068477-19276544-F495-459E-848D-E2791051213DQ47094795-0347079A-E8DD-40FF-8069-759B8E4BDC53Q47599265-2080E842-EEEC-4D19-AAA5-552026DDB334Q47777234-2B95701C-945B-4973-AB31-C42FEA57A727Q48512265-0BB20644-0CF2-4A5B-B405-A4F0D6235CB5Q52679023-13C95AAB-CFF8-41CC-A545-708C1863AD23Q52814108-D8B48D21-1A4C-4CA0-BB83-AFF8EAABBA87Q54967334-9889FBB9-2099-4861-AB18-6C06BC98E256Q55262467-AC2C4542-DFE0-4729-909D-8E3D26FF032DQ55327976-0F2DABD3-2B78-482C-BF65-F306400CCF36Q57137770-159629B7-B6D4-4061-9094-8D78240D397AQ58761533-38FE9115-782D-4707-9087-4D7D2FD6F53DQ58804389-C73F7F03-A197-4660-B2A9-187A0E3B7675Q58804575-DC34A7CF-00DA-40D9-9370-3B6F095650ABQ59135403-6C0E26A8-6160-4080-8135-CE1DEA7E79E3
P2860
Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase
description
2016 nî lūn-bûn
@nan
2016 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Discovery of Brigatinib (AP261 ...... of Anaplastic Lymphoma Kinase
@ast
Discovery of Brigatinib (AP261 ...... of Anaplastic Lymphoma Kinase
@en
Discovery of Brigatinib (AP261 ...... of Anaplastic Lymphoma Kinase
@nl
type
label
Discovery of Brigatinib (AP261 ...... of Anaplastic Lymphoma Kinase
@ast
Discovery of Brigatinib (AP261 ...... of Anaplastic Lymphoma Kinase
@en
Discovery of Brigatinib (AP261 ...... of Anaplastic Lymphoma Kinase
@nl
prefLabel
Discovery of Brigatinib (AP261 ...... of Anaplastic Lymphoma Kinase
@ast
Discovery of Brigatinib (AP261 ...... of Anaplastic Lymphoma Kinase
@en
Discovery of Brigatinib (AP261 ...... of Anaplastic Lymphoma Kinase
@nl
P2093
P3181
P1476
Discovery of Brigatinib (AP261 ...... of Anaplastic Lymphoma Kinase
@en
P2093
Angela Toms
Anna Kohlmann
David Dalgarno
Frank Wang
Hyun Gyung Jang
Jan Romero
Jeffrey Keats
P304
P3181
P356
10.1021/ACS.JMEDCHEM.6B00306
P407
P577
2016-05-26T00:00:00Z